Want to see JP:3386 full AI Analyst Report?
Cosmo Bio Co., Ltd. (3386) AI Stock Analysis
Cosmo Bio Co., Ltd.
(TSE/TYO:3386)
The overall score is led by the company's pristine, zero-debt balance sheet and a compelling 3.98% dividend yield, providing a robust safety net and strong income potential. Technical indicators point to steady consolidation above long-term moving averages. The primary constraint on the score is ongoing margin compression, which remains the key operational challenge to maximizing shareholder value.
Cosmo Bio Co., Ltd. (3386) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 7.04B
- Dividend Yield
- 4.05%
- Average Volume (3M)
- 4,486
- Price to Earnings (P/E)
- 19.3
- Beta (1Y)
- 0.30
- Revenue Growth
- 9.39%
- EPS Growth
- 44.42%
- Country
- Japan
- Employees
- 182
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Cosmo Bio Co., Ltd. Business Overview & Revenue Model
Company Description
Cosmo Bio Company, Limited is a key player in the life science research sector, involved in the global import, export, manufacturing, marketing, and distribution of essential biotools. Their extensive product line includes biochemical reagents, speci...
How the Company Makes Money
Cosmo Bio primarily makes money by selling research-use-only life science products and related services to laboratories. Its revenue model is largely transaction-based and is supported by (1) product sales from its own brands and manufacturing activi...
Cosmo Bio Co., Ltd. Financial Statement Overview
Summary
The score reflects a fortress balance sheet with negligible debt and recovering operating cash flows. However, overall profitability is tempered by ongoing margin compression despite the company achieving record top-line revenue.
Income Statement
55NeutralBalance Sheet
88Very PositiveCash Flow
72Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.28B | 10.77B | 10.04B | 9.34B | 9.55B | 9.23B |
| Gross Profit | 3.88B | 3.70B | 3.33B | 3.25B | 3.44B | 3.66B |
| EBITDA | 562.00M | 509.00M | 455.00M | 801.00M | 931.00M | 1.26B |
| Net Income | 363.00M | 336.00M | 262.00M | 442.00M | 517.00M | 737.00M |
Balance Sheet | ||||||
| Total Assets | 12.84B | 12.66B | 11.72B | 10.87B | 10.31B | 10.07B |
| Cash, Cash Equivalents and Short-Term Investments | 4.07B | 2.95B | 2.69B | 3.02B | 3.04B | 3.56B |
| Total Debt | 737.00M | 20.00M | 22.00M | 24.00M | 27.00M | 28.00M |
| Total Liabilities | 2.49B | 2.70B | 2.17B | 1.84B | 1.69B | 1.75B |
| Stockholders Equity | 9.76B | 9.37B | 8.97B | 8.45B | 8.05B | 7.79B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 366.00M | 25.00M | 636.00M | 180.00M | 507.00M |
| Operating Cash Flow | 0 | 595.00M | 241.00M | 736.00M | 284.00M | 648.00M |
| Investing Cash Flow | 0 | 43.00M | -217.00M | -758.00M | -291.00M | -145.00M |
| Financing Cash Flow | 0 | -283.00M | -479.00M | -201.00M | -236.00M | -420.00M |
Cosmo Bio Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3386, the sentiment is Negative. The current price of 1236.00 is below the 20-day moving average (MA) of 1242.75, below the 50-day MA of 1247.34, and below the 200-day MA of 1255.21, indicating a bearish trend. The MACD of -6.60 indicates Positive momentum. The RSI at 47.19 is Neutral, neither overbought nor oversold. The STOCH value of 43.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3386.
Cosmo Bio Co., Ltd. Peers Comparison
Overall Rating
- JP:338671Outperform
JP:457068Neutral
JP:489245Neutral
JP:497842Neutral
JP:777626Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:3386 | 71Outperform | JPY 7.16B | 19.27 | ― | 4.05% | 9.39% | 44.42% |
| JP:4570 | 68Neutral | JPY 9.56B | 25.97 | ― | 0.58% | 13.46% | 42.41% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4892 | 45Neutral | JPY 5.64B | -6.87 | ― | ― | 364.72% | 18.43% |
| JP:4978 | 42Neutral | JPY 13.03B | -26.58 | ― | ― | -18.71% | -246.54% |
| JP:7776 | 26Underperform | JPY 7.43B | -6.49 | ― | ― | -56.16% | 3.12% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:3386 | Cosmo Bio Co., Ltd. | 1236.00 | 135.82 | 12.34% | |
| JP:4570 | Immuno-Biological Laboratories Co., Ltd. | 1027.00 | 563.99 | 121.81% | |
| JP:4892 | Cyfuse Biomedical K.K. | 559.00 | -26.00 | -4.44% | |
| JP:4978 | ReproCELL Inc. | 122.00 | -51.00 | -29.48% | |
| JP:7776 | CellSeed Inc. | 188.00 | -249.00 | -56.98% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 04, 2026